- Home
- / SillaJen
SillaJen
Stock Price
₩2.5 K
2024-10-29
Market Capitalization
₩340.5 B
2024-10-29
Revenue
₩9.2 B
FY, 2025
SillaJen Summary
Company Summary
- Overview
- SillaJen is a biotechnology company focused on engineering and developing oncolytic virus immunotherapeutics. It offers Pexa-Vec, a Wyeth strain vaccinia virus engineered to directly lyse tumor cells and stimulate anti-tumor immunity, and JX-970, a pipeline for the treatment of tumor tissues.
- Type
- Public
- Status
- Active
- Founded
- 2003
- HQ
- KR | view all locations
- Website
- http://www.sillajen.com/
- Cybersecurity rating
- ESG rating
Table of Contents
LocationsView all
3 locations detected
Seoul HQ
Korea (Republic of)
83 Uisadang-daero, Yeoeuido-dong, Yeongdeungpo-gu
San Francisco, CA
United States
475 Sansome St #740, San Francisco
Busan
Korea (Republic of)
Hyoyeol-ro, Geumgok-dong, Buk-gu
SillaJen Financials
Summary Financials
- Revenue (FY, 2025)
- ₩9.2B
- Gross profit (FY, 2025)
- ₩9.9B
- Net income (FY, 2025)
- (₩24.2B)
- Cash (FY, 2025)
- ₩5.3B
- EBIT (FY, 2025)
- (₩25.7B)
- Enterprise value
- $337.5B
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026